These seemingly inconsistent observations suggest that the B cell signature may be a potential predictive biomarker associated with the efficacy of anti-PD-1-based treatment in patients with advanced ESCC because it does not exhibit prognostic significance in patients with ESCC of earlier stages not receiving ICI treatment. The gene discussed is PDCD1; the disease is esophageal squamous cell carcinoma.